Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

NCT01561417 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Bleeding Disorder
Acquired Haemophilia
Congenital Bleeding Disorder
Congenital FVII Deficiency
Glanzmann's Disease
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors
Healthy

Interventions

DRUG: activated recombinant human factor VII
DRUG: activated recombinant human factor VII

Sponsor

Novo Nordisk A/S